Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investm.

Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date

The consensus price target hints at a 57% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know

Simulations Plus (SLP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?

FlexShares STOXX US ESG Impact Index Fund

LANCASTER, Calif.--(BUSINESS WIRE)--CEO of Simulations Plus, Shawn O'Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on Monday, November 25, 2024.

Simulations Plus to Participate in the BTIG Digital Health Forum

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional LAI product technologies.

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

The consensus price target hints at a 77.5% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Simulations Plus (SLP)? Wall Street Analysts Think 77.52%

LANCASTER, Calif.--(BUSINESS WIRE)--Shawn O'Connor, CEO, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 20, 2024 at 12:00pm ET.

Simulations Plus to Participate in the Stephens Annual Investment Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, with industry and academic partners, was awarded a new FDA grant to validate new methods for more efficient drug development.

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations

SLP's fiscal fourth-quarter performance is driven by healthy revenue growth across its software and services business segments.

Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth

Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript

Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago.

Simulations Plus (SLP) Surpasses Q4 Earnings Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported fiscal year 2024 total revenues of $70 million, 18% over fiscal 2023, and 4th quarter total revenues of $18.7 million.

Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 23, 2024, at 5pm ET to discuss 4th quarter & fiscal year 2024 financial results.

Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with USC, is awarded a new research grant from the NIH to develop new AI-driven Drug Design methods.

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's Global Healthcare Conference on September 6, 2024, in New York City.

Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Simulations Plus, Inc. SLP has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.

Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced strategic changes in leadership and the structure of its business units to optimize operations and support future growth.

Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus released DILIsym X, its flagship QST platform, with important enhancements to expedite and improve predictions regarding drug safety.

Simulations Plus Releases DILIsym® X

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor 12, a major upgrade to its machine-learning modeling platform for drug discovery, design, & optimization.

Simulations Plus Releases ADMET Predictor® Version 12

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be presenting at KeyBanc's 25th Annual Technology Leadership Forum in Vail, CO, on Monday, August 5, 2024.

Simulations Plus to Participate in KeyBanc's 25th Annual Technology Leadership Forum

Simulations Plus, Inc. SLP has entered into a partnership with the International Collaboration on Cosmetics Safety (“ICCS”) to develop a physiologically-based kinetic (PBK) read-across strategy for diverse chemicals and exposure routes (intravenous, oral and dermal) across virtual populations of humans and rodents. This collaboration aims to establish procedural workflows and guidelines for integrating these methods into animal-free safety assessments.

Simulations Plus (SLP) Ties Up With ICCS for Chemical Safety

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was selected for a new project with the International Collaboration on Cosmetics Safety to advance animal-free safety assessments.

Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety

Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%.

Simulations Plus Stock Drops 15% Despite EPS Beat

Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units.

Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates

First Foundation

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday.

News for Simulations Plus Stock (SLP)